DIAGNOS, following a successful Proof-of-Concept (POC) pilot study, is finalising its new application CARA-STROKE to address ...
March 09 2021 - 9:05AM
Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces today the final step of the
development of its STROKE predictor (CARA-ST) based on images of
the retina. Following the completion of a successful POC pilot
study with over 3,000 patients, DIAGNOS is now ready to proceed
with clinical trials.
As per the Centers for Disease Control and
Prevention (CDC), strokes are the cause of 1 out of every 20
deaths, representing a cost of approximately 34 billion USD per
year in the United States. According to the World Health
Organization, 15 million people suffer a stroke
worldwide each year. Of these, 5 million die and
another 5 million are permanently disabled. High blood pressure
contributes to more than 85% of strokes
worldwide. Europe averages
approximately 650,000 stroke related
deaths each year.
Hence, early diagnosis and treatment to prevent
deaths from stroke is a time sensitive necessity. Stroke prevention
devices are currently used to reduce the risk of a recurrent stroke
in patients and have been shown to lower the overall risk.
“CARA-ST will be able to predict the viability
of developing a stroke condition based on the micro circulation
analysis of the retina image of the patient. DIAGNOS has been
developing this technology for the last four years and because of
the conditions brought on by the COVID-19 pandemic, we were able to
expedite the final testing and development of our new application,”
said Mr. Riadh Kobbi, Vice President Data Science at
DIAGNOS.
“According to new reports published by worldwide
research institutes, the market size for Stroke Management will hit
over $36 Billion dollars by 2023. DIAGNOS intends to be part of the
solution by making available an affordable predictive test to the
general public. At DIAGNOS we have continued to invest in Research
and Development, furthering the creation of our intellectual
property by partnering with Quebec government programs and local
university (ETS) to ensure we stay ahead of competition worldwide.
This year our new stroke management application will be field
tested in multiple countries. For our investors this
ground-breaking test comes at an ideal time in terms of shareholder
value creation as the combination of both CARA-DR and CARA-ST tools
will be transformational in helping to monitor the health of
existing and future CV patients,” said Mr. André Larente,
President of DIAGNOS.
About DIAGNOS DIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based of its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s AI-based image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024